Abbott Laboratories moves to acquire cancer-testing leader Exact Sciences in a landmark deal, signaling a strategic shift toward high-growth diagnostics while simultaneously restructuring its challenged Nutrition business.
CNBC's Jim Cramer tempered enthusiasm for Novo Nordisk stock, suggesting investors hold rather than buy after its massive gains driven by blockbuster weight-loss drugs.
While Wall Street chases the latest weight-loss drug headlines, Novo Nordisk's recent launch of an oral GLP-1 therapy and its entrenched insulin business present a compelling value proposition for long-term investors.
While Medtronic's shares have trailed the S&P 500 over the past year, Wall Street maintains a cautiously optimistic stance, buoyed by strong recent earnings and raised guidance.
As the wearables market surges, Biolinq CEO Richard Yang positions smart patches as the next evolution, capable of tracking deep biochemical data where watches track surface metrics, with his company's FDA-cleared glucose sensor leading the charge.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.
While small-cap stocks offer significant growth potential, their volatility demands careful selection. We analyze one standout and two struggling companies in the Russell 2000 index this week.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility dedicated to next-generation weight-loss drugs, signaling a long-term strategic commitment to the obesity market amid intense competition.
The vital Rafah border crossing between Gaza and Egypt reopened Monday for strictly limited passenger traffic, marking a tentative step in the implementation of the Israel-Hamas ceasefire. The move, described as largely symbolic for now, offers a glimmer of hope for thousands of Palestinians seeking medical care or a return home.
Christie Oster, a recently honored middle school educator in Lafayette Parish, faces serious felony charges following allegations of an inappropriate relationship with a former student, casting a shadow over her celebrated career.
Medtronic's expanded partnership with Mindray integrates its monitoring technologies into ASC-focused platforms, a strategic move to embed itself in a high-growth segment while analysts debate its impact on the broader investment thesis.
Novo Nordisk's newly launched oral GLP-1 drug, amycretin, has seen explosive initial demand in the U.S., potentially setting the stage for a significant financial turnaround and stock rally after a challenging previous year.
While fully autonomous robotic surgeons remain on the horizon, the foundational technology and data ecosystems being built today are setting the stage for a transformative shift. Two industry giants, Intuitive Surgical and Medtronic, offer investors distinct pathways to capitalize on this evolving landscape.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Citi raises Lexicon Pharmaceuticals' price target to $2.10, citing strong momentum from its collaboration with Novo Nordisk on obesity drug candidate LX9851 and improved financials.
While small-cap stocks can offer unique growth opportunities away from Wall Street's spotlight, their inherent risks demand careful scrutiny. We examine three companies where valuation concerns and competitive pressures suggest caution may be warranted.
DexCom Inc. (DXCM) has released preliminary Q4 figures that exceeded expectations and provided robust long-term guidance, reinforcing its position as a favored pick among analysts and hedge funds in the medical devices sector.
Despite near-term headwinds in its Nutrition segment, Abbott Laboratories (ABT) maintains a bullish long-term outlook with solid organic sales growth projected for 2026, even as major analysts adjust their price targets following Q4 results.
A recent physician survey on renal denervation procedure volumes has prompted analysts to adopt a more measured view of Medtronic's near-term growth potential, even as the medical device giant remains a favored long-term holding.
